Genetic studies have revealed that in MPN patients, the Janus kinase 2 (JAK2) V617F mutation is found in the vast majority of PV patients (95%) and in approximately 50% of ET and PMF patients [3, 4]. Here, JAK2 is linked to essential thrombocythemia.